All‐cause mortalityg · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (deaths during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
It is very uncertain whether the intervention changes mortality (deaths during trial period) (very low certainty).
1 finding from 1 review
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Disease-free survival · Adults with oropharyngeal cancer
Surgery showed no clear difference in disease-free survival (new disease, progression, and mortality) compared with radiotherapy alone (low certainty).
1 finding from 1 review
Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy
ESA with or without iron showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.46 [0.87, 2.43]
Studies not reported
Low
On‐study mortality3 (Subnet based on 55 studies including 15,074 participants) · patients at any age with solid cancer or haematological malignancy
ESA with or without iron showed no clear difference in on‐study mortality3 (Subnet based on 55 studies including 15,074… compared with no treatment (low certainty).
1 finding from 1 review
RR 0.13 [0.01, 2.29]
Studies not reported
Low